Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Marco Ladetto, Rita Tavarozzi, Matthew Ku, Luca Arcaini, Carola Boccomini, Beatrice Casadei, Annalisa Chiarenza, Annarita Conconi, Ilaria Del Giudice, Michele Merli, Maria Elena Nizzoli, Stefano Luminari

Blood (2024) 144 (Supplement 1): 3042.1.

https://doi.org/10.1182/blood-2024-201305

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry

Blood (2024) 144 (Supplement 1): 1650.

https://doi.org/10.1182/blood-2024-200166

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Deepa Jagadeesh, Silvana Novelli, Stefano Luminari, Michal Taszner, Michele Merli, Yingzxin Xu, Siddhesh Kamat, Liza Mastikhina, Srikanth Ambati, Jenny Chen, Keith Chan, Shannon Cope, Sam Keeping, Clyde Caisip, Hesham Mohamed, Aafia Chaudhry, James Harnett, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 7803.

https://doi.org/10.1182/blood-2024-200865

Published: 2024

Journal Articles

PET Radiomics Discriminate Among Different Lymphoma Sub-Types

Stephane Chauvie, Lale Kostakoglu Shields, Luca Guerra, Annibale Versari, Federico Fallanca, Michele Gregianin, Fabrizio Bergesio, Enrica Bergalla, Adriano De Maggi, Denis Sahin, Rexhep Durmo, Umberto Vitolo, Massimo Federico, Andrea Gallamini, Alessandro Rambaldi, Stefano Luminari

Blood (2024) 144 (Supplement 1): 7505.

https://doi.org/10.1182/blood-2024-205170

Published: 2024

Journal Articles

Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma

Tanja Lazic, Benedetta Donati, Maria Elena Nizzoli, Alberto Bavieri, Rexhep Durmo, Riccardo Valli, Attilio Gennaro, Cristian Ascione, Alessia Ruffini, Stefano Pozzi, Annibale Versari, Francesco Merli, Stefano Luminari, Alessia Ciarrocchi

Blood (2024) 144 (Supplement 1): 6205.

https://doi.org/10.1182/blood-2024-207696

Published: 2024

Journal Articles

The Prognostic Value of MTV Is Retained in New Proposed SUV 4 Threshold: An International Comparison of Follicular and Hodgkin Patient Survival

Stephane Chauvie, Luca Guerra, Federico Fallanca, Michele Gregianin, Annibale Versari, Rexhep Durmo, Fabrizio Bergesio, Adriano De Maggi, Enrica Bergalla, Alessandro Rambaldi, Simone Ferrero, Caterina Patti, Massimo Federico, Andrea Gallamini, Stefano Luminari

Blood (2024) 144 (Supplement 1): 6254.

https://doi.org/10.1182/blood-2024-206736

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry

Blood (2024) 144 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2024-200259

Published: 2024

Journal Articles

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Blood (2024) 144 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2024-207163

Published: 2024

Journal Articles

Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study

Stefano Luminari, Jose C. Villasboas Bisneto, Geoffrey Chong, David Tucker, Srikanth Ambati, Chinjune Lin, Hesham Mohamed, C. Akunna Otele, Giovanni Antico, Ana Jiménez Ubieto

Blood (2024) 144 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2024-199100

Published: 2024

Journal Articles

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Monia Marchetti, Paolo Corradini, Luca Arcaini, Stefania Bramanti, Alice Di Rocco, Marco Ladetto, Stefano Luminari, Luigi Rigacci, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2024-198647

Published: 2024

Journal Articles

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Noemi Puccio, Elisa Taiana, Gloria Manzotti, Elisabetta Mereu, Domenica Ronchetti, Cecilia Bandini, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Veronica Manicardi, Valentina Fragliasso, Nicola Amodio, Niccolò Bolli, Stefano Luminari, Alessia Ciarrocchi, Roberto Piva, Antonino Neri

Blood (2023) 142 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2023-190131

Published: 2023

Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic

Blood (2023) 142 (Supplement 1): 427.

https://doi.org/10.1182/blood-2023-179812

Published: 2023

Journal Articles

Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

Catherine Thieblemont, Annarita Conconi, Christian Buske, Stefano Luminari, Martin Dreyling, Maria Gomes da Silva, Marc Andre, Maria Flores, Karima Brahami-Aissou, Pascale Cony-Makhoul, Sylvain Carras

Blood (2023) 142 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2023-180473

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford

Blood (2023) 142 (Supplement 1): 612.

https://doi.org/10.1182/blood-2023-185818

Published: 2023

Journal Articles

Hells (LSH) Controls Gene Expression in T-Cell Lymphomas By Regulating RNA Polymerase II with a Bimodal Function

Valentina Fragliasso, Veronica Manicardi, Annalisa Tameni, Selene Mallia, Benedetta Donati, Federica Torricelli, Emanuele Vitale, Magda Zanelli, Stefano Luminari, Stefano Ascani, Francesca Sanguedolce, Noemi Puccio, Antonino Neri, Alessia Ciarrocchi

Blood (2023) 142 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2023-177555

Published: 2023

NARROW

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

PET Radiomics Discriminate Among Different Lymphoma Sub-Types

Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma

The Prognostic Value of MTV Is Retained in New Proposed SUV 4 Threshold: An International Comparison of Follicular and Hodgkin Patient Survival

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Hells (LSH) Controls Gene Expression in T-Cell Lymphomas By Regulating RNA Polymerase II with a Bimodal Function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only